Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement

Matthew D.F. McInnes*, David Moher, Brett D. Thombs, Trevor A. McGrath, Patrick M. Bossuyt, Tammy Clifford, Jérémie F. Cohen, Jonathan J. Deeks, Constantine Gatsonis, Lotty Hooft, Harriet A. Hunt, Christopher J. Hyde, Daniël A. Korevaar, Mariska M.G. Leeflang, Petra Macaskill, Johannes B. Reitsma, Rachel Rodin, Anne W.S. Rutjes, Jean Paul Salameh, Adrienne StevensYemisi Takwoingi, Marcello Tonelli, Laura Weeks, Penny Whiting, Brian H. Willis, PRISMA-DTA Group

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)

380 Citations (Scopus)
319 Downloads (Pure)

Abstract

Importance: Systematic reviews of diagnostic test accuracy synthesize data from primary diagnostic studies that have evaluated the accuracy of 1 or more index tests against a reference standard, provide estimates of test performance, allow comparisons of the accuracy of different tests, and facilitate the identification of sources of variability in test accuracy.

Objective: To develop the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagnostic test accuracy guideline as a stand-alone extension of the PRISMA statement. Modifications to the PRISMA statement reflect the specific requirements for reporting of systematic reviews and meta-analyses of diagnostic test accuracy studies and the abstracts for these reviews.

Design: Established standards from the Enhancing the Quality and Transparency of Health Research (EQUATOR) Network were followed for the development of the guideline. The original PRISMA statement was used as a framework on which to modify and add items. A group of 24 multidisciplinary experts used a systematic review of articles on existing reporting guidelines and methods, a 3-round Delphi process, a consensus meeting, pilot testing, and iterative refinement to develop the PRISMA diagnostic test accuracy guideline. The final version of the PRISMA diagnostic test accuracy guideline checklist was approved by the group.

Findings: The systematic review (produced 64 items) and the Delphi process (provided feedback on 7 proposed items; 1 item was later split into 2 items) identified 71 potentially relevant items for consideration. The Delphi process reduced these to 60 items that were discussed at the consensus meeting. Following the meeting, pilot testing and iterative feedback were used to generate the 27-item PRISMA diagnostic test accuracy checklist. To reflect specific or optimal contemporary systematic review methods for diagnostic test accuracy, 8 of the 27 original PRISMA items were left unchanged, 17 were modified, 2 were added, and 2 were omitted.

Conclusions and Relevance: The 27-item PRISMA diagnostic test accuracy checklist provides specific guidance for reporting of systematic reviews. The PRISMA diagnostic test accuracy guideline can facilitate the transparent reporting of reviews, and may assist in the evaluation of validity and applicability, enhance replicability of reviews, and make the results from systematic reviews of diagnostic test accuracy studies more useful.

Original languageEnglish
Pages (from-to)388-396
Number of pages9
JournalJAMA - Journal of the American Medical Association
Volume319
Issue number4
Early online date23 Jan 2018
DOIs
Publication statusPublished - Jan 2018

Fingerprint Dive into the research topics of 'Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement'. Together they form a unique fingerprint.

  • Cite this

    McInnes, M. D. F., Moher, D., Thombs, B. D., McGrath, T. A., Bossuyt, P. M., Clifford, T., Cohen, J. F., Deeks, J. J., Gatsonis, C., Hooft, L., Hunt, H. A., Hyde, C. J., Korevaar, D. A., Leeflang, M. M. G., Macaskill, P., Reitsma, J. B., Rodin, R., Rutjes, A. W. S., Salameh, J. P., ... PRISMA-DTA Group (2018). Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA - Journal of the American Medical Association, 319(4), 388-396. https://doi.org/10.1001/jama.2017.19163